Benchmark analyst Mike Hickey reiterates Marcus (NYSE:MCS) with a Buy and maintains $20 price target.
PDS Biotech Reports Median Overall Survival Of 21 Months In Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options With Reported Historical Survival Of 3-4 months
PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced expanded interim data
